Nanosonics Limited (NAN) AI Stock Analysis

• Market Cap: $1.45B
• Dividend Yield: N/A
• Average Volume (3M): 1.03M
• Price to Earnings (P/E): 87.4
• Beta (1Y): 0.55
• Revenue Growth: 10.79%
• EPS Growth: 5.20%
• Country: AU
• Employees: 466
• Sector: Healthcare
• Sector Strength: 46
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.03
• Shares Outstanding: 303,599,460
• 10 Day Avg. Volume: 845,393
• 30 Day Avg. Volume: 1,029,165
• PEG Ratio: -5.84
• Price to Book (P/B): 7.21
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 64.95
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $4.93
• Price Target Upside: 1.36% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 8

Nanosonics Limited's stock is supported by strong financial performance and positive earnings call highlights, particularly in revenue growth across key regions. The technical analysis suggests upward momentum, although high valuation metrics pose a risk. Despite some regional challenges, the company's strategic initiatives and solid financial standing offer a favorable outlook.

Nanosonics Limited Business Overview & Revenue Model

Company Description

Nanosonics Limited (NAN) is an Australian-based company specializing in infection prevention solutions in the healthcare sector. The company's flagship product, the trophon® EPR, is a high-level disinfection system used for ultrasound probes, offering a safer and more efficient method of disinfection. Nanosonics is committed to developing innovative technologies that enhance patient safety and protect healthcare workers from infection risks.

How the Company Makes Money

Nanosonics Limited generates revenue primarily through the sale and distribution of its trophon® EPR disinfection systems and related consumables. The company employs a razor-and-blades business model, where initial revenue is earned from selling the trophon® units, and ongoing revenue is derived from consumable items necessary for the system's operation, such as disinfectant cartridges and cleaning wipes. Additionally, Nanosonics benefits from service contracts and maintenance agreements, which provide a steady stream of income over time. The company also engages in partnerships and collaborations with healthcare organizations and equipment distributors to expand its market reach and drive sales growth.

Nanosonics Limited Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
171.56M	167.51M	119.73M	101.83M	99.38M
	Gross Profit
133.99M	125.66M	86.15M	74.91M	71.09M
	EBIT
9.12M	18.00M	792.00K	8.38M	11.66M
	EBITDA
21.72M	29.50M	7.86M	15.75M	16.70M
	Net Income Common Stockholders
12.97M	19.88M	3.74M	8.58M	10.14M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
129.55M	112.16M	94.51M	96.03M	91.78M
	Total Assets
237.34M	226.07M	193.24M	164.57M	148.23M
	Total Debt
9.30M	10.72M	11.71M	2.49M	2.61M
	Net Debt
-120.25M	-101.44M	-82.80M	-93.54M	-89.17M
	Total Liabilities
55.14M	62.22M	54.55M	29.01M	24.00M
	Stockholders Equity
182.20M	163.86M	138.69M	135.57M	124.23M
Cash Flow		Free Cash Flow
20.27M	19.74M	-271.00K	5.93M	20.83M
	Operating Cash Flow
22.78M	23.31M	6.70M	7.32M	22.76M
	Investing Cash Flow
-2.36M	-3.54M	-6.90M	-1.38M	-1.94M
	Financing Cash Flow
-3.01M	-2.71M	-1.97M	-1.03M	-1.30M

Nanosonics Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.86
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NAN, the sentiment is Positive. The current price of 4.86 is above the 20-day moving average (MA) of 4.72, above the 50-day MA of 4.63, and above the 200-day MA of 3.65, indicating a bullish trend. The MACD of 0.08 indicates Negative momentum. The RSI at 56.95 is Neutral, neither overbought nor oversold. The STOCH value of 77.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:NAN.

Nanosonics Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RMD	79 Outperform	AU$55.94B	27.90	25.23%	0.82%	10.54%	38.69%
NAN	76 Outperform	$1.45B	87.36	9.23%	―	10.79%	5.20%
COH	68 Neutral	$17.48B	47.61	20.61%	1.65%	6.35%	5.97%
CSL	64 Neutral	$121.28B	29.85	15.38%	1.90%	8.00%	9.09%
RHC	55 Neutral	AU$8.43B	1,030.34	0.52%	2.40%	7.25%	-99.04%
Sector *	52 Neutral	$5.15B	3.56	-42.52%	2.83%	14.56%	-0.50%

Nanosonics Limited Corporate Events

Nanosonics CEO Adjusts Shareholdings to Address Tax Obligations

Nanosonics Limited announced a change in the director’s interest, with CEO Michael Kavanagh selling 100,000 ordinary shares to cover a tax liability from exercising company securities. Despite the sale, Kavanagh retains a significant holding of 1,256,723 shares and 1,569,840 rights, indicating continued confidence in the company’s prospects.

ECP Asset Management and EC Pohl & Co Cease Substantial Holding in Nanosonics Limited

Nanosonics Limited announced that ECP Asset Management Pty Ltd and EC Pohl & Co Pty Ltd have ceased to be substantial holders in the company as of March 21, 2025. This change in substantial holding could impact the company’s shareholder structure and influence its market positioning, potentially affecting investor perceptions and stakeholder interests.

Nanosonics Secures FDA Clearance for CORIS® System

Nanosonics Limited has received FDA De Novo clearance for its CORIS® system, a novel technology aimed at reducing infection risks and improving cleaning outcomes for flexible endoscopes. This clearance marks a significant milestone for the company, with plans for a commercial launch in Q1 FY26, initially targeting a controlled market release in select hospitals before a broader rollout.

Nanosonics Director Increases Shareholding, Signaling Confidence

Nanosonics Limited announced a change in the director’s interest, with Gerard Dalbosco acquiring 7,442 ordinary shares, bringing his total to 27,442 shares. This transaction, valued at $32,372.70, reflects continued confidence in the company’s market position and potential growth, potentially impacting stakeholders’ perception positively.

Nanosonics Limited Announces Quotation of New Securities

Nanosonics Limited has announced the application for quotation of 43,298 ordinary fully paid securities on the Australian Securities Exchange. This move is part of an employee incentive scheme and indicates the company’s ongoing efforts to incentivize its workforce, potentially impacting its operational dynamics and market position positively.

Nanosonics Updates on Director’s Interest Notice

Nanosonics Limited announced a change in the director’s interest notice due to an acquisition of performance rights by CEO Michael Kavanagh. The company acknowledged a delay in lodging the notice due to an administrative oversight and has since reviewed its procedures to ensure compliance with ASX listing rules.

Nanosonics Corrects Security Classification Error in Recent Announcement

Nanosonics Limited has issued an update to a previous announcement regarding the classification of securities. Initially reported as ordinary fully paid shares due to a selection error, the correct classification is NANAO Performance Rights, with 2,248,299 rights issued under the Nanosonics Employee Equity Plan. This correction clarifies the nature of the securities involved, which may impact stakeholders’ understanding of the company’s equity structure.

Nanosonics Director Acquires 20,000 Shares

Nanosonics Limited has announced a change in the director’s interest, with Gerard Dalbosco acquiring 20,000 ordinary shares in the company. This acquisition, valued at approximately $87,139.75, reflects a significant investment by the director, potentially indicating confidence in the company’s future performance and strategic direction.

Nanosonics Director Increases Stake in Company

Nanosonics Limited announced a change in the director’s interest, with Director Tracey Leigh Batten acquiring an additional 15,715 ordinary shares, bringing her total to 30,000 shares. This transaction, valued at approximately $73,941.07, indicates a significant increase in her stake, potentially reflecting confidence in the company’s future performance.

Nanosonics Reports Strong 2025 Half-Year Financial Results

Nanosonics Limited reported a strong financial performance for the first half of 2025, with an 18% increase in total revenue to $93.6 million and a 41% rise in profit before tax from its trophon business. The company continues to strengthen its position in North America, Europe, and APAC regions, driven by expansion in installed base and consumables revenue, while also preparing for the commercial launch of its new CORIS technology.

Nanosonics Reports Strong Half-Year Financial Performance

Nanosonics Limited reported an 18% increase in revenue to $93.6 million for the half-year ending December 2024, with a notable 124% rise in profit before tax. The results reflect strong operational performance and market demand, positioning the company favorably in the infection prevention industry. Despite the growth, no dividends were distributed during this period, and there were no changes in control over entities.